Refractory Lymphocytic Enterocolitis and Tumor Necrosis Factor Antagonist Therapy

Ghazaleh Aram, Theodore M. Bayless, Zong Ming Chen, Elizabeth A. Montgomery, Mark Donowitz, Francis M. Giardiello

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background & Aims: Lymphocytic enterocolitis is a malabsorptive syndrome characterized by severe small-bowel villous abnormality and crypt hyperplasia and dense infiltrate of lymphocytes throughout the gastrointestinal tract. Methods: We present 2 patients with lymphocytic enterocolitis refractory to usual medical therapy who were treated with tumor necrosis factor antagonists. Results: Both patients had clinical improvement in diarrheal symptoms and intestinal histologic abnormalities. Conclusions: Tumor necrosis factor-α antagonists such as infliximab or adalimumab may be a new treatment option for patients with severe refractory lymphocytic enterocolitis not responding to corticosteroids.

Original languageEnglish (US)
Pages (from-to)391-394
Number of pages4
JournalClinical Gastroenterology and Hepatology
Issue number4
StatePublished - Apr 2010


  • Diarrhea
  • Lymphocytic Enterocolitis
  • Refractory Sprue
  • Tumor Necrosis Factor Antagonist

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Refractory Lymphocytic Enterocolitis and Tumor Necrosis Factor Antagonist Therapy'. Together they form a unique fingerprint.

Cite this